Literature DB >> 23340223

Nicotine-morphine interactions at α4β2, α7 and α3(⁎) nicotinic acetylcholine receptors.

Reeta Talka1, Outi Salminen, Paul Whiteaker, Ronald J Lukas, Raimo K Tuominen.   

Abstract

Nicotine and opioids share several behavioral and rewarding properties. Although both opioids and nicotine have their own specific mechanism of action, there is empirical and experimental evidence of interactions between these drugs. We studied receptor-level interactions of nicotine and morphine at α4β2, α7 and α3(⁎) nicotinic acetylcholine receptors. [(3)H]epibatidine displacement was used to determine if morphine binds competitively to nicotinic acetylcholine receptors. Functional interactions of morphine and nicotine were studied with calcium fluorometry and (86)Rb(+) efflux assays. Morphine displaced [(3)H]epibatidine from nicotinic agonist binding sites in all cell lines studied. The Ki values for morphine were 13.2μM in SH-EP1-hα4β2 cells, 0.16μM and 126μM in SH-SY5Y cells and 43.7μM in SH-EP1-hα7 cells. In SH-EP1-hα4β2 cells expressing α4β2 nicotinic acetylcholine receptors, morphine acted as a partial agonist of (86)Rb(+) efflux comparable to cytisine (with EC50 values of 53.3μM for morphine and 5.38μM for cytisine). The effect of morphine was attenuated concentration-dependently by the nicotinic antagonist mecamylamine. In the SH-SY5Y cell line expressing several subtypes of nicotinic acetylcholine receptors morphine had an inhibitory effect on nicotine induced (86)Rb(+) ion efflux mediated by α3(⁎) nicotinic acetylcholine receptors. These results suggest that morphine acts as a partial agonist at α4β2 nicotinic acetylcholine receptors and as a weak antagonist at α3(⁎) nicotinic acetylcholine receptors.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23340223     DOI: 10.1016/j.ejphar.2013.01.005

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Morphine dependence and withdrawal induced changes in cholinergic signaling.

Authors:  Nichole M Neugebauer; Emily B Einstein; Maria B Lopez; Tristan D McClure-Begley; Yann S Mineur; Marina R Picciotto
Journal:  Pharmacol Biochem Behav       Date:  2013-05-04       Impact factor: 3.533

2.  African-specific variability in the acetylcholine muscarinic receptor M4: association with cocaine and heroin addiction.

Authors:  Orna Levran; Matthew Randesi; Einat Peles; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2016-06-07       Impact factor: 2.533

3.  Mechanisms and Clinical Features of Co-occurring Opioid and Nicotine Use.

Authors:  Sarah D Lichenstein; Yasmin Zakiniaeiz; Sarah W Yip; Kathleen A Garrison
Journal:  Curr Addict Rep       Date:  2019-04-27

4.  Nicotinic modulation of descending pain control circuitry.

Authors:  Iboro C Umana; Claire A Daniele; Brooke A Miller; Chandrika Abburi; Keith Gallagher; Meghan A Brown; Peggy Mason; Daniel S McGehee
Journal:  Pain       Date:  2017-10       Impact factor: 7.926

5.  Low dose nicotine attenuates Aβ neurotoxicity through activation early growth response gene 1 pathway.

Authors:  Maoqiang Xue; Liuwei Zhu; Jie Zhang; Jinhua Qiu; Guicheng Du; Zhiliang Qiao; Guanghui Jin; Fengguang Gao; Qiqing Zhang
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

6.  Interaction of nicotine with morphine potency in Paramecium caudatum.

Authors:  Seyed Sajad Shahrokhi; Mahnaz Kesmati; Bahram Kazemi
Journal:  Heliyon       Date:  2019-08-23

Review 7.  Nicotine Gateway Effects on Adolescent Substance Use.

Authors:  Michelle Ren; Shahrdad Lotfipour
Journal:  West J Emerg Med       Date:  2019-08-20

8.  Effect of mu Agonists on Long-Term Survival and Recurrence in Nonsmall Cell Lung Cancer Patients.

Authors:  Kai Wang; Xiao Qu; Ying Wang; Hongchang Shen; Qi Liu; Jiajun Du
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.